News & Events Year None201820172016201520142013201220112009 08/08/18 REGENXBIO Reports Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia 08/07/18 REGENXBIO to Host Conference Call and Webcast on August 8 to Discuss Second Quarter 2018 Financial and Operating Results and Interim Data from Ongoing Clinical Trials for Wet Age-Related Macular Degeneration and Homozygous Familial Hypercholesterolemia 08/01/18 REGENXBIO to Host Conference Call on August 8 to Discuss Second Quarter 2018 Financial Results and Recent Operational Highlights 06/12/18 REGENXBIO Receives FDA Fast Track Designation for RGX-111 Gene Therapy for the Treatment of Mucopolysaccharidosis Type I 06/11/18 REGENXBIO Receives $100 Million Accelerated License Payment Due to Acquisition of AveXis by Novartis 05/29/18 Alexandra Glucksmann Joins REGENXBIO Board of Directors 05/15/18 REGENXBIO Joins the Mucopolysaccharidosis Community to Advance Research and Innovation Pagination First page « first Previous page ‹ previous Page 1 Current page 2 Page 3 Page 4 Next page next › Last page last »
